Producer
Toray Medical Co., Ltd.
Tokyo-based subsidiary of Toray Industries that manufactures the Filtryzer line of PMMA (polymethyl methacrylate) dialyzer membranes — the only commercially available adsorptive dialyzer membrane globally. Filtryzer adsorbs middle-molecular-weight uremic toxins and cytokines rather than filtering by convection/diffusion alone, offering a differentiated clinical benefit unavailable in PSU or CTA dialyzers.
1
Inputs supplied
0
Goods downstream
0
Facilities
0
Stories
What they make
1 input Toray Medical Co., Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Filtryzer® PMMA Dialyzers (Adsorptive Membrane)
60%Bloodlines & Dialysis Circuit Disposables
25%Parent Company Context: Toray Industries (Advanced Materials)
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Chokepoint2023
Toray Medical's PMMA (polymethyl methacrylate) dialyzer membrane (Filtryzer product line) is the only commercially available adsorptive dialyzer membrane globally. While all other dialyzers filter uremic toxins by diffusion/convection, Filtryzer adsorbs middle-molecular-weight toxins and inflammatory cytokines onto the PMMA surface — clinically beneficial for septic patients and those with high inflammatory burden. Toray Medical is the sole global supplier of this distinct membrane technology.
Toray Medical Co., Ltd. ↗Did you know2023
Toray Industries — globally recognized as the maker of Torayca carbon fiber used in Boeing 787 Dreamliner structural airframes — is also, through its Toray Medical subsidiary, the world's only producer of PMMA (polymethyl methacrylate) hollow fiber adsorptive dialyzer membranes. This makes Toray Industries a life-critical materials monopolist across three entirely separate supply chains: (1) Torayca carbon fiber → Boeing and Airbus composite airframes → commercial aviation; (2) ROMEMBRA reverse osmosis membranes → seawater desalination → potable water for millions in Saudi Arabia, Singapore, and the UAE; (3) Filtryzer PMMA dialyzer membranes → kidney failure treatment. The parent company that manufactures the structural skin of modern commercial aircraft is the same company that makes the artificial kidney membrane for dialysis patients in Japan — from the same fiber spinning and membrane manufacturing technology platform.
Toray Industries, Inc. ↗Origin2023
Toray Medical Co., Ltd. is a subsidiary of Toray Industries — a Japanese advanced materials conglomerate best known for Torayca® carbon fiber, the structural material used in Boeing 787 and Airbus A350 aircraft. Toray Industries' core competency is spinning ultrafine, high-performance organic fibers into functional forms. Carbon fiber (Torayca), polyester fiber (Toray's textiles), ROMEMBRA reverse osmosis water treatment membranes, and PMMA hollow fiber dialyzer membranes (Toray Medical) are all expressions of the same core capability — precisely controlling polymer fiber geometry and surface chemistry at the nano-to-micro scale. A company founded as a synthetic fiber maker in 1926 Osaka evolved into the supplier of structural carbon fiber for commercial aircraft AND the dialysis membrane for kidney patients AND the desalination membranes providing drinking water to the Middle East.
Toray Industries, Inc. ↗Capacity2023
Toray Medical's Filtryzer PMMA dialyzer is the only adsorptive dialyzer membrane available commercially, with 100% market share in this specific product category. PMMA dialyzers are predominantly used in Japan — Japanese clinical practice includes routine use of high-flux PMMA dialyzers for inflammatory complications in dialysis patients. Toray Medical has no competitive pressure in this niche because the hollow fiber spinning technology for PMMA membranes is complex, the clinical market is Japan-centric (limiting global commercial attractiveness for Western entrants), and Toray holds the proprietary know-how. This creates an unusual monopoly: a product with proven clinical differentiation (adsorption of protein-bound toxins), no commercial competition, and a captive clinical market in Japan — yet largely unknown outside nephrology circles.
Toray Medical Co., Ltd. ↗